for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aurobindo Pharma Ltd

ARBN.NS

Latest Trade

906.45INR

Change

-3.30(-0.36%)

Volume

7,555,414

Today's Range

898.00

 - 

923.00

52 Week Range

288.85

 - 

923.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
909.75
Open
914.00
Volume
7,555,414
3M AVG Volume
102.03
Today's High
923.00
Today's Low
898.00
52 Week High
923.00
52 Week Low
288.85
Shares Out (MIL)
585.94
Market Cap (MIL)
533,057.60
Forward P/E
16.92
Dividend (Yield %)
0.33

Next Event

Q1 2021 Aurobindo Pharma Ltd Earnings Release

Latest Developments

More

Aurobindo Pharma March Quarter Consol Profit Rises

Aurobindo Pharma Paid Settlement Amount Of 22 Mln Rupees To SEBI

Aurobindo Pharma Gets USFDA Approval For Flucytosine Capsules

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.

Industry

Major Drugs

Contact Info

Water Mark Building,, Plot No. 11

Survey no.9, Kondapur, Hitech City

Hyderabad,Telangana

500084

India

+91.40.66725000

https://www.aurobindo.com/

Executive Leadership

K. Ragunathan

Non-Executive Independent Chairman of the Board

K. Nityananda Reddy

Whole-Time Vice Chairman of the Board, a promoter of the Company

Santhanam Subramanian

Chief Financial Officer

B. Adi Reddy

Compliance Officer, Company Secretary

N. Govindarajan

Managing Director, Executive Director

Key Stats

1.63 mean rating - 30 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

162.3K

2019

195.6K

2020

231.0K

2021(E)

252.1K
EPS (INR)

2018

41.360

2019

41.860

2020

48.770

2021(E)

53.767
Price To Earnings (TTM)
18.83
Price To Sales (TTM)
2.31
Price To Book (MRQ)
3.17
Price To Cash Flow (TTM)
14.04
Total Debt To Equity (MRQ)
33.83
LT Debt To Equity (MRQ)
1.57
Return on Investment (TTM)
17.70
Return on Equity (TTM)
10.22

Latest News

Latest News

BRIEF-Aurobindo Pharma Says 'Form 483' Issued With 9 Observations After USFDA Inspection Of Dayton, New Jersey Plant

* 'FORM 483' HAS BEEN ISSUED WITH 9 OBSERVATIONS AFTER US FDA INSPECTION OF DAYTON, NEW JERSEY PLANT

BRIEF-Aurobindo Pharma March Quarter Consol Profit Rises

* MARCH QUARTER CONSOL NET PROFIT 8.5 BILLION RUPEES VERSUS 5.85 BILLION RUPEES

BRIEF-Aurobindo Pharma Paid Settlement Amount Of 22 Mln Rupees To SEBI

* PAID SETTLEMENT AMOUNT OF 22 MILLION RUPEES TO SEBI FOR ORDER AGAINST CO AND CERTAIN PROMOTERS

BRIEF-Aurobindo Pharma Gets USFDA Approval For Flucytosine Capsules

* AUROBINDO PHARMA LTD SAYS GETS USFDA APPROVAL FOR FLUCYTOSINE CAPSULES

BRIEF-Aurobindo Pharma Says U.S. FDA Determined That Inspection Classification Of Co's Facility Is Voluntary Action Indicated

* U.S. FDA HAS DETERMINED THAT INSPECTION CLASSIFICATION OF CO'S FACILITY IS VOLUNTARY ACTION INDICATED Source text for Eikon: Further company coverage:

BRIEF-Aurobindo Pharma Ltd -Receives USFDA Approval For Fluoxetine Tablets

* AUROBINDO PHARMA LTD -AUROBINDO PHARMA RECEIVES USFDA APPROVAL FOR FLUOXETINE TABLETS Source text for Eikon: Further company coverage:

UPDATE 1-Novartis scraps sale of assets including COVID-19 hopeful to India's Aurobindo

* Cancellation blow to CEO's plan to focus on higher-margin drugs (Adds details, background)

Novartis scraps sale of assets to Aurobindo Pharma after failing to get FTC nod

Novartis AG said on Thursday it had scrapped the sale of its U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd after failing to get approval from a U.S. regulator.

BRIEF-Aurobindo Pharma Ltd -Terminates Agreement To Buy Sandoz US Generic Oral Solids, Dermatology Businesses

* AUROBINDO PHARMA LTD -ANNOUNCES MUTUAL AGREEMENT WITH SANDOZ INC TO TERMINATE AGREEMENT TO BUY SANDOZ US GENERIC ORAL SOLIDS, DERMATOLOGY BUSINESSES

BRIEF-Aurobindo Pharma Says U.S. FDA's VAI Issued On Feb 18 Rescinded

* GETS NOTICE THAT INSPECTION AT UNIT IV BY U.S. FDA STILL OPEN AND UNDER REVIEW

BRIEF-Aurobindo Pharma Gets VAI Status From U.S. FDA For Facility

* AUROBINDO PHARMA LTD -RECEIVED EIR WITH VOLUNTARY ACTION INITIATED STATUS FROM USFDA FOR UNIT 4, INJECTABLE FORMULATION MANUFACTURING FACILITY Source text for Eikon: Further company coverage:

BRIEF-Novartis says Zolgensma delay in Europe, Japan due to manufacturing questions from regulators

* SANDOZ Q3 OPERATING INCOME WAS USD 191 MILLION (-47%, -42% CC) IMPACTED BY CHANGES IN LEGAL SETTLEMENT PROVISIONS, HIGHER NET MANUFACTURING AND SANDOZ TRANSFORMATION RESTRUCTURING EXPENSES AND LOWER DIVESTMENT INCOME

Takeda unit sues Aurobindo to block generic Velcade

A U.S. unit of Japan's Takeda Pharmaceutical Co has sued generic drugmaker Aurobindo Pharma Ltd over its plans to make a cheaper version of Takeda's cancer drug Velcade.

Aurobindo Pharma to recall 80 lots of blood pressure medicine valsartan in the U.S.

A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration.

India's Aurobindo Pharma Q2 profit falls nearly 22 pct

Aurobindo Pharma Ltd, India's second-largest drugmaker by market capitalisation, posted a 21.7 percent fall in its second-quarter profit on Monday, hurt by higher expenses, but beat analysts' estimates.

Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo

New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd for up to $1 billion.

Novartis sells parts of Sandoz US to India's Aurobindo for $900 mln

Novartis AG said on Thursday it would sell the dermatology and generic U.S. oral solids portfolios of Sandoz U.S. to India's Aurobindo Pharma Ltd for $900 million, as the Swiss drugmaker looks to focus on higher growth areas.

BRIEF-Novartis Says To Divest Sandoz U.S. Dermatology Business And Generic U.S. Oral Solids Portfolio To Aurobindo

* NOVARTIS TO DIVEST SANDOZ US DERMATOLOGY BUSINESS AND GENERIC US ORAL SOLIDS PORTFOLIO TO AUROBINDO

BRIEF-Aurobindo Pharma Unit To Buy Commercial Ops And 3 Manufacturing Facilities From Sandoz

* UNIT AUROBINDO PHARMA USA ENTERED DEAL TO BUY COMMERCIAL OPERATIONS AND THREE MANUFACTURING FACILITIES IN USA FROM SANDOZ ., USA

India's Aurobindo Pharma Q4 profit misses estimates

India's Aurobindo Pharma Ltd posted a 0.6 percent fall in fourth-quarter net profit on Monday that missed analysts' estimates.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up